<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01832558</url>
  </required_header>
  <id_info>
    <org_study_id>EudraCT: 2012-002175-34</org_study_id>
    <nct_id>NCT01832558</nct_id>
  </id_info>
  <brief_title>The EPOCH Study (Eplerenone on Top of ACE Inhibition in Chronic Kidney Disease Patients With Hypertension)</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <brief_summary>
    <textblock>
      In a prospective single centre placebo-controlled trial over ten weeks, 24 CKD II-III
      patients (eGFR 30-89 ml/min per 1.73 m2) with DM II will be randomized to enalapril 20mg per
      day after a two week run-in phase. Thereafter, patients will either receive eplerenone 25mg
      (n=12) or a placebo (n=12) for eight weeks. Eplerenone will be increased to 50mg under close
      monitoring of serum potassium levels. Employing a novel mass-spectrometry ( MS)-based method,
      quantification of up to 10 different Ang metabolites (Ang I, Ang II, Ang 1-7, Ang 1-9, Ang
      2-10, Ang 1-5, Ang 2-7, Ang 3-7, Ang 3-8 and Ang 2-8) will be performed simultaneously out of
      blood sera (after run-in phase and after 10 weeks).
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Angiotensin levels (pg/ml) of CKD II-III patients with DM II with eplerenone additional to enalapril in comparison to patients who receive a placebo on top of enalapril therapy.</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <condition>CKD II-III</condition>
  <arm_group>
    <arm_group_label>Eplerenone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eplerenone 25-50mg daily additionally to standard ACE-inhibition with enalapril 20mg daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo additionally to standard ACE-inhibition with enalapril 20mg daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eplerenone</intervention_name>
    <arm_group_label>Eplerenone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  CKD II to III and diabetes mellitus type 2

          -  CKD will be defined according to estimated glomerular filtration rate (eGFR) with the
             MDRD formula

          -  eGFR between 30 and 89 ml/min

          -  albumin excretion rates &gt; 300 mg/24 hours (UACR &gt; 300 mg/gram) or &gt; 200 mg/g if
             already receiving any RAS blockade Patients should be hypertonic stage I or II
             according to the European guidelines (Chobanian et al. JAMA 2003)

        Exclusion Criteria:

          -  Age &lt; 18 years

          -  UACR &gt; 3500mg/g

          -  severe hypertension

          -  pregnancy

          -  unwilling or inability to sign the informed consent

          -  coronary heart disease

          -  systolic blood pressure &lt; 130 mmHg

          -  additional RAS interfering drugs (ACEis, ARBs, direct renin inhibitors)

          -  25-hydroxy vitamin D levels below 16.6±8.3 pg/ml

          -  1,25-dihydroxy vitamin D 33.1±15.5 pg/ml

        Intolerance to eplerenon or an excipient of it:

        tablettcore: Lactose-Monohydrat Mikrokristalline Cellulose (E 460) Croscarmellose-sodium (E
        468) Hypromellose (E 464) Sodiumdodecylsulfat Talkum (E 553b) Magnesiumstearat (E 470b)

        filmcoat

        Opadry, yellow:

        Hypromellose (E 464) Titandioxid (E 171) Macrogol 400 Polysorbat 80 (E 433) Yellow
        ironoxide (E 172) Red ironoxide (E 172)

          -  Patients with Serumpotassium &gt; 5,0 mmol/l at start of the treatment

          -  Patients with severe renal insufficiency (eGFR &lt;30ml/min./1.73 m2)

          -  Patients with severe liver insufficiency (Child-Pugh class C)

          -  Patients taking potassium saving diuretics, potassium supplements or strong
             CYP3A4-inhibitors (z. B. Itraconazol, Ketoconazol, Ritonavir, Nelfinavir,
             Clarithromycin, Telithromycin und Nefazodon)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Marcus Saemann, MD</last_name>
    <phone>0043/404005593</phone>
    <email>marcus.saemann@meduniwien.ac.at</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcus Saemann, MD</last_name>
      <phone>01/40400/5593</phone>
      <email>marcus.saemann@meduniwien.ac.at</email>
    </contact>
    <investigator>
      <last_name>Johannes Kovarik, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <reference>
    <citation>Shavit L, Lifschitz MD, Epstein M. Aldosterone blockade and the mineralocorticoid receptor in the management of chronic kidney disease: current concepts and emerging treatment paradigms. Kidney Int. 2012 May;81(10):955-68. doi: 10.1038/ki.2011.505. Epub 2012 Feb 15. Review.</citation>
    <PMID>22336987</PMID>
  </reference>
  <reference>
    <citation>Epstein M, Williams GH, Weinberger M, Lewin A, Krause S, Mukherjee R, Patni R, Beckerman B. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin J Am Soc Nephrol. 2006 Sep;1(5):940-51. Epub 2006 Jul 19.</citation>
    <PMID>17699311</PMID>
  </reference>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 8, 2013</study_first_submitted>
  <study_first_submitted_qc>April 15, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 16, 2013</study_first_posted>
  <last_update_submitted>March 14, 2016</last_update_submitted>
  <last_update_submitted_qc>March 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Marcus Saemann</investigator_full_name>
    <investigator_title>Assoc. Prof. Priv.-Doz. Dr.med.univ.</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eplerenone</mesh_term>
    <mesh_term>Spironolactone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

